Haffejee I E
J Antimicrob Chemother. 1984 Sep;14 Suppl B:147-52. doi: 10.1093/jac/14.suppl_b.147.
A single-blind therapeutic trial, using randomly either cefotaxime or a benzyl-penicillin-gentamicin combination, was carried out in 68 hospitalised paediatric patients with 72 episodes of severe infection, which were, in the main, septicaemia, pneumonia, neonatal meningitis and a few other miscellaneous infections. The cefotaxime group showed a cure rate of 94.4% compared with 72.2% in the other group. One patient with bacterial meningitis treated initially with cefotaxime died a month later; however, penicillin and chloramphenicol had been added due to clinical deterioration. In the penicillin-gentamicin group there were five deaths, all from suspected neonatal septicaemia, and three cases required a change in antibiotic regimen before a cure could be effected. The results indicate that cefotaxime should be considered a drug of choice in many neonates with life-threatening sepsis.
对68例住院的儿科患者共72次严重感染发作进行了一项单盲治疗试验，这些感染主要是败血症、肺炎、新生儿脑膜炎和其他一些杂类感染，随机使用头孢噻肟或苄青霉素-庆大霉素联合用药。头孢噻肟组的治愈率为94.4%，而另一组为72.2%。1例最初用头孢噻肟治疗的细菌性脑膜炎患者1个月后死亡；然而，由于临床病情恶化，已加用青霉素和氯霉素。在青霉素-庆大霉素组中有5例死亡，均死于疑似新生儿败血症，3例在治愈前需要更换抗生素治疗方案。结果表明，头孢噻肟应被视为许多患有危及生命败血症的新生儿的首选药物。
